Literature DB >> 1586239

Increased risk of cancer in patients with systemic lupus erythematosus.

T Pettersson1, E Pukkala, L Teppo, C Friman.   

Abstract

To evaluate the risk of cancer in patients with systemic lupus erythematosus (SLE) a series of 205 consecutive patients (182 women and 23 men) were followed up for cancer through the files of the Finnish Cancer Registry. The follow up consisted of a total of 2340 person years. Fifteen cancers were diagnosed against 5.7 expected (relative risk (RR) 2.6, 95% confidence interval (CI) 1.5 to 4.4). Among the women there were four non-Hodgkin's lymphomas against 0.09 expected (RR 44, CI 11.9 to 111) and two soft tissue sarcomas against 0.04 expected (RR 49, CI 6.0 to 177). When evaluated by a case control study previous treatment with cytostatic drugs showed no influence on the occurrence of cancer in this series of patients with SLE.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1586239      PMCID： PMC1004687          DOI： 10.1136/ard.51.4.437

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  15 in total

1.  THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME.

Authors:  N TALAL; J J BUNIM
Journal:  Am J Med       Date:  1964-04       Impact factor: 4.965

Review 2.  The relationship between autoimmune states and B cell proliferations.

Authors:  R Bataille; B Klein; B G Durie
Journal:  J Rheumatol       Date:  1989-08       Impact factor: 4.666

3.  Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases.

Authors:  D T Boumpas; G C Tsokos; D L Mann; E G Eleftheriades; C C Harris; G E Mark
Journal:  Arthritis Rheum       Date:  1986-06

Review 4.  Cancer in autoimmune diseases.

Authors:  O Sela; Y Shoenfeld
Journal:  Semin Arthritis Rheum       Date:  1988-11       Impact factor: 5.532

5.  Immunoregulatory aberrations in systemic lupus erythematosus.

Authors:  A S Fauci; A D Steinberg; B F Haynes; G Whalen
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

Review 6.  Autoimmune and immunoproliferative diseases of NZB/Bl mice and hybrids.

Authors:  R C Mellors
Journal:  Int Rev Exp Pathol       Date:  1966

Review 7.  Normal, autoimmune, and malignant CD5+ B cells: the Ly-1 B lineage?

Authors:  K Hayakawa; R R Hardy
Journal:  Annu Rev Immunol       Date:  1988       Impact factor: 28.527

8.  Cancer in connective tissue disease.

Authors:  K A Black; P J Zilko; R L Dawkins; B K Armstrong; G L Mastaglia
Journal:  Arthritis Rheum       Date:  1982-09

9.  Systemic lupus erythematosus with paraproteinemia.

Authors:  L Rubin; M B Urowitz; W Pruzanski
Journal:  Arthritis Rheum       Date:  1984-06

10.  Systemic lupus erythematosus and lymphoma.

Authors:  J A Green; A A Dawson; W Walker
Journal:  Lancet       Date:  1978-10-07       Impact factor: 79.321
View more
  40 in total

Review 1.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review.

Authors:  Iuri Usêda Santana; Alline do Nascimento Gomes; Leomar D'Cirqueira Lyrio; Maria Fernanda Rios Grassi; Mittermayer Barreto Santiago
Journal:  Clin Rheumatol       Date:  2010-10-31       Impact factor: 2.980

2.  Systemic lupus erythematosus and malignancies risk.

Authors:  Song Mao; Hua Shen; Jianhua Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-29       Impact factor: 4.553

Review 3.  Revisiting the issue of malignancy risk in systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

4.  Cancer risk in systemic lupus: an updated international multi-centre cohort study.

Authors:  Sasha Bernatsky; Rosalind Ramsey-Goldman; Jeremy Labrecque; Lawrence Joseph; Jean-Francois Boivin; Michelle Petri; Asad Zoma; Susan Manzi; Murray B Urowitz; Dafna Gladman; Paul R Fortin; Ellen Ginzler; Edward Yelin; Sang-Cheol Bae; Daniel J Wallace; Steven Edworthy; Soren Jacobsen; Caroline Gordon; Mary Anne Dooley; Christine A Peschken; John G Hanly; Graciela S Alarcón; Ola Nived; Guillermo Ruiz-Irastorza; David Isenberg; Anisur Rahman; Torsten Witte; Cynthia Aranow; Diane L Kamen; Kristjan Steinsson; Anca Askanase; Susan Barr; Lindsey A Criswell; Gunnar Sturfelt; Neha M Patel; Jean-Luc Senécal; Michel Zummer; Janet E Pope; Stephanie Ensworth; Hani El-Gabalawy; Timothy McCarthy; Lene Dreyer; John Sibley; Yvan St Pierre; Ann E Clarke
Journal:  J Autoimmun       Date:  2013-02-12       Impact factor: 7.094

5.  Correlation between systemic lupus erythematosus and malignancies: a cross-sectional population-based study.

Authors:  Shir Azrielant; Shmuel Tiosano; Abdulla Watad; Naim Mahroum; Aaron Whitby; Doron Comaneshter; Arnon D Cohen; Howard Amital
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

Review 6.  Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review.

Authors:  Takanori Ichikawa; Yasuhiro Shimojima; Dai Kishida; Tomoki Kaneko; Yoshiki Sekijima
Journal:  Rheumatol Int       Date:  2020-04-06       Impact factor: 2.631

Review 7.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

8.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2008-04-02       Impact factor: 2.506

9.  Clastogenic factors as potential biomarkers of increased superoxide production.

Authors:  Ingrid Emerit
Journal:  Biomark Insights       Date:  2007-12-11

10.  Primary osteosarcoma of the urinary bladder following cyclophosphamide therapy for systemic lupus erythematosus: a case report.

Authors:  Dilek Ertoy Baydar; Cigdem Himmetoglu; Sertac Yazici; Halil Kiziloz; Haluk Ozen
Journal:  J Med Case Rep       Date:  2009-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.